PReS-FINAL-2328: Developing and validating the new severity score for FMF by unknown
POSTER PRESENTATION Open Access
PReS-FINAL-2328: Developing and validating
the new severity score for FMF
E Demirkaya*, C Acikel, A Gul, M Gattorno, E Ben-Chetrit, H Ozdogan, P Hashkes, A Polat, A Livneh, S Ozen
From 20th Pediatric Rheumatology European Society (PReS) Congress
Ljubljana, Slovenia. 25-29 September 2013
Introduction
One of the main features, in the follow-up of a patient
with a chronic disorder is severity. Definition in severity
is quite difficult since the disease manifests with various
clinical and laboratory features. On the other hand,
there have been many articles reported in literature
about the lack of consistency between currently used
severity scores such as Mor, Pras and Tel Hashomer
criteria.
Objectives
The aim of this study was to develop and validate a new
set of criteria for the assessment of disease severity for
FMF patients by a multicenter study.
Methods
After three rounds of Delphi survey, an elite expert
panel that consisted of ten rheumatologists and one
facilitator gathered in a consensus meeting in November
2012. The candidate criteria which were defined after
Delphi rounds were discussed in the consensus meeting,
potential criteria set were purified and the description of
each item was ascertained. In order to evaluate the
validity of criteria set, each expert brought together the
data of clinical, laboratory manifestations and physician’s
global assessments of 10-50 patients from their center.
Logistic regression analysis was used to evaluate predict-
able value of each item and ROC curve analysis was per-
formed to demonstrate the success of the criteria set.
Results
In expert panel nine items were selected as the identi-
fiers of severity. Area under the curve (AUC) was calcu-
lated as 0,825 for this criteria set. When each item was
evaluated individually, renal failure, nephrotic
proteinuria and mean duration of episodes had the least
contribution to prediction of severity. Besides, in logistic
regression analysis these criteria were eliminated from
the terminal modal. After reducing the criteria set, AUC
was calculated as 0,808. Additional analysis demon-
strated that the reduced model was as successful as full
model. AUC was higher than 0,75 in both pediatric and
adult patient groups and the results were better in adult
group.
Conclusion
Initial validation analysis showed that the scale could be
used in assessing severity in FMF patients. The valida-
tion of the criteria should be performed on FMF
patients attending outpatient clinics in routine visits.
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